Recent Updates
Recently added Catalysts
RIGL Positive Sentiment

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

Wednesday, November 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Rigel Pharmaceuticals, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. Dean Schorno, the CFO, will provide a company overview during the event. Investors can access the live webcast through the company's website, ensuring they connect beforehand for any necessary software downloads.
Price reaction · baseline $49.56 (2025-11-25 close) · hit pre-market · clean, no other RIGL news in the window
day 0 close · peak
+2.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Rigel Pharmaceuticals is actively engaging in investor relations.
  • The presentation at a notable healthcare conference highlights company visibility.
  • The company focuses on improving therapies for hematologic disorders and cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+9%
120-day peak, hindsight
Typical move
12.1%
average across 2 past catalysts
Lead asset
Fostamatinib
Phase 2 · Acute Respiratory Distress Syndrome

Full Press Release Details

SOUTH SAN FRANCISCO, Calif.,Nov. 26, 2025/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Piper Sandler 37thAnnual Healthcare Conference on Wednesday, December 3, 2025, at 8:30 am ET.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website atwww.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About RigelRigel Pharmaceuticals, Inc. (Nasdaq:RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visitwww.rigel.com.

Contact for Investors & Media:Investors:Rigel Pharmaceuticals, Inc.650.624.1232[email protected]

Media:David RosenArgot Partners646.461.6387[email protected]

Frequently Asked Questions

When will Rigel present at the Piper Sandler conference?

Rigel will present on December 3, 2025, at 8:30 am ET.

Who will present for Rigel at the conference?

Dean Schorno, the CFO of Rigel, will present at the conference.

How can I access the Rigel presentation?

You can access the live webcast on Rigel's Investor Relations webpage.

What is Rigel Pharmaceuticals focused on?

Rigel focuses on developing therapies for hematologic disorders and cancer.

ShareAdd on Google
Tags: RIGL Viatris Investor Conferences Healthcare Rigel Pharmaceuticals Piper Sandler healthcare conference biotechnology hematologic disorders
Last updated: Nov 26, 2025

Biotech snapshot

Cash runway
$95M liquidity · $0M/mo burn
Low dilution risk
Lead asset
FostamatinibPhase 2
Acute Respiratory Distress Syndrome →

Catalyst track record

+9%
best trade around RIGL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for RIGL.

See every catalyst's timing & PoA →